StockNews.com downgrades Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to retain

0

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) was downgraded by stock analysts to StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Other equity research analysts have also recently published research reports on the company. JPMorgan Chase & Co. cut its price target on Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a Monday, August 1 report. Truist Financial lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a Wednesday, June 22 report . Berenberg Bank cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a Wednesday, August 10 report. Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from an “underperform” rating to a “buy” rating and raised its target price for the stock from $30.30 to 33.70 $ in a Monday, June 27 report. Finally, DZ Bank downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 report. One equity research analyst has assigned the stock a sell rating, eight have issued a hold rating and three have assigned the stock a buy rating. Based on MarketBeat data, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and an average price target of $45.83.

Fresenius Medical Care AG & Co. KGaA Stock down 0.2%

A d Legacy search

The 3-share pension plan

When most people think of making money in the markets, they think “buy and hold”. They think “diversification”. And they think about investing in things like index funds. But one man has a different approach…

NYSE:FMS was down $0.04 during Thursday trading hours, hitting $17.67. The company had a trading volume of 778,360 shares, compared to an average volume of 664,176. The company’s 50-day simple moving average is $21.65 and its two-hundred-day simple moving average is 28 .11$. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $17.00 and a 12-month high of $39.71. The company has a market capitalization of $10.36 billion, a price/earnings ratio of 11.25, a P/E/G ratio of 0.89 and a beta of 1.02. The company has a quick ratio of 0.85, a current ratio of 1.18 and a debt ratio of 0.47.

Institutional investors weigh in on Fresenius Medical Care AG & Co. KGaA

A number of hedge funds have recently changed their FMS holdings. SRS Capital Advisors Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 36.0% in Q1. SRS Capital Advisors Inc. now owns 1,545 shares of the company valued at $52,000 after buying 409 additional shares in the last quarter. Signaturefd LLC increased its stake in the shares of Fresenius Medical Care AG & Co. KGaA by 26.4% during the 1st quarter. Signaturefd LLC now owns 2,190 shares of the company valued at $74,000 after purchasing an additional 458 shares during the period. Dimensional Fund Advisors LP increased its holdings in Fresenius Medical Care AG & Co. KGaA by 1.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 53,824 shares of the company worth $1,747,000 after buying 516 additional shares in the last quarter. Timber Creek Capital Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 0.3% during the second quarter. Timber Creek Capital Management LLC now owns 199,285 shares of the company valued at $4,970,000 after purchasing an additional 542 shares last quarter. Finally, Wetherby Asset Management Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 9.0% in the 1st quarter. Wetherby Asset Management Inc. now owns 6,807 shares of the company valued at $229,000 after purchasing an additional 560 shares last quarter. Institutional investors hold 4.73% of the company’s shares.

About Fresenius Medical Care AG & Co. KGaA

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Further reading

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.